ProCE Banner Activity

NSABP B-59/GBG-96-GeparDouze: Phase III Trial of Neoadjuvant CT Plus Atezolizumab Followed by Adjuvant Atezolizumab for Stage II/III TNBC

Conference Coverage
Slideset

Results from the phase III NSABP B-59/GBG-96-GeparDouze trial in triple-negative breast cancer showed that neoadjuvant CT with atezolizumab followed by adjuvant atezolizumab did not prolong event-free survival compared with the placebo control arm, but did increase pCR rate.

Released: December 18, 2024

Expiration: December 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation